Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX. A systematic review of utility estimates in melanoma in the adjuvant setting. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.
Heyes A, McBride D, Pearson I, Copley-Merriman C. HTA and reimbursement considerations for rare diseases in European markets: what are the implications for manufacturers? Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine. 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736
Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal. 2018 Jun 28;6(2):9-20.
Mordin M, Fernandez M, Pearson I, Copley-Merriman K, McBride D. Similarities and differences in European HTA evidence requirements: one for all or one for none? Presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.
Copley-Merriman K. Rare diseases: addressing the challenges in diagnosis, drug approval, and patient access - editorial. Value Health. 2018 May;21(5):491-2. doi: 10.1016/j.jval.2018.03.009
Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic Literature Review (SLR) of sequencing of Anaplastic Lymphoma Kinase (ALK) inhibitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49-50. doi: 10.1016/j.jval.2018.04.291
Fernandez MM, Khan S, Mordin M, Copley-Merriman C, McBride D. Comparing literature review requirements for reimbursement submissions across the globe. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.732
Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Arbuckle R, Atkinson MJ, Clark M, Abetz L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Peytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Health Qual Life Outcomes. 2008 Oct 16;6:80. doi: 10.1186/1477-7525-6-80.
Copley-Merriman C, Fehnel SE, Chandler J, Wild D. Obtaining a patient-reported outcomes label claim: what evidence do you need? Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008.